A TRAILBLAZING company, a leader in the field of genetic toxicology, is continuing to expand.

Leading contract research organisation Gentronix at Alderley Park in has introduced a new service range in response to increasing global demand, driving further growth for the business.

Gentronix provides companies developing new chemical or pharmaceutical products with toxicology tests required by regulators to show that they are safe to use.

READ > Warning as car thefts rise in Knutsford, Wilmslow and Alderley Edge

The company employs more than 40 staff, including a team of expert toxicologists and serves clients including top five pharmaceutical, chemical and agrochemical organisaitons.

A new service capability has been introduced to its expanding toxicology offering, the 96-Well MNT with automated slide scoring.

The new assay will enable Gentronix to provide faster turnaround times, allowing rapid project decision-making with minimal compound requirements.

Automated scoring results in faster delivery of data than manual slide scoring methods, allowing for quicker delivery of project timelines. T his new service will strengthen Gentronix’ ability to support clients in meeting their deadlines, identifying potential hazards and manage risk for their materials.

The addition to Gentronix’s portfolio comes shortly after the company announced a further laboratory and office expansion in April, as part of the firm’s ongoing growth plans.

Previous expansions have accommodated increased capacity for its genetic toxicology screening services and genetic, ocular, and skin toxicology testing - growing the Gentronix footprint at Alderley Park by 30 per cent.

Matt Tate, chief executive officer at Gentronix said: “We are committed to providing the highest quality science for our expanding global client base.

“By adding the 96-Well MNT with automated slide scoring to our service capabilities, it will enable us to deliver even faster turnaround times for our clients and their projects.

“We are continuing our business growth journey this year and have already invested considerable effort into expanding our facilities and capacity and creating more high-quality jobs for the UK life science sector.”

By adding new services and increasing genetic toxicology service capacity to the market, Gentronix can turn round requests and testing quickly, with significant commercial advantages for clients, whilst facilitating the growth of their own business.

As a leading predictive toxicology contract research organisation, Gentronix’s work helps develop safe products used by millions of people around the world including pharmaceuticals, agrochemicals, fragrances, foods, flavours, personal care products and cosmetics.